Novartis AG has gained FDA approval to market Kisqali (ribociclib), in combination with an aromatase inhibitor, as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor positive (HR+), HER2-negative advanced or metastatic breast cancer. Read More
Scott Gottlieb’s nomination as the next FDA commissioner is garnering support from industry, but it’s generating some opposition from other quarters. Read More
LONDON – The leading vaccines manufacturers have a mixed record when it comes to improving access to their products in poorer countries, according to the first Access to Vaccines Index, published last week. Read More
Members of the osteoarthritis (OA) community came together last week under the banner of the Arthritis Foundation for the first externally led Patient-Focused Drug Development (PFDD) meeting to address the indication. Read More
The results of a new Taiwanese study into the little known role of circular RNA (circRNA) in colorectal cancer (CRC) pathogenesis suggest a new approach is needed to treatment of the cancer, in which therapy should not only target proteins, but also non-protein coding RNAs. Read More
Like the fusion of two Indian words to form its name, Vedantra Pharmaceuticals Inc. is seeking to blend multiple technology platforms to develop therapeutic vaccines that target cancer and infectious disease. Read More
Aequus Pharmceuticals Inc., of Vancouver, British Columbia, said it closed its public offering issuing 17.25 million units at $0.30 each, for aggregate gross proceeds of C$5.175 million (US$3.85 million). Read More
Neurim Pharmaceuticals Ltd., of Tel Aviv, Israel, granted Biocodex exclusive rights to market its investigational pediatric melatonin drug, Rx Pedprm, in France. The drug is targeted to treat sleep disorders in children with autism spectrum disorders and neurogenetic diseases. Read More
Houston-based Celltex Therapeutics Corp. said that favorable responses in two pediatric rheumatoid arthritis patients treated with autologous mesenchymal stem cell therapy processed by the company warrant further clinical trials. Read More
